Feasibility of the interferon-gamma enzyme-linked immunospot assay in chronic renal failure patients and immunocompetent subjects: a head-to-head comparison

Dilektaşlı, Aslı Görek; Durukan, Elıf; Eyüboğlu, Füsun Öner

doi:10.3109/0886022x.2014.979508

Cited by 1 publication

(1 citation statement)

References 34 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IGRAs include proteins that are more unique and specific to Mtb than those in the purified derivative (PPD) and that are 4 encoded by genes located in the region of difference 1 (RD 1) within the Mtb genome. These genes are not found in M. bovis BCG or most environmental mycobacteria [7]. The QuantiFERON-TB Gold In-Tube test (QFT-GIT) assay (Cellestis, Carniege, Victoria, Australia) measures the IFN-γ concentration in whole blood after stimulation by specific tuberculosis antigens (e.g., early secreted antigenic target-6 [ESAT-6], culture filtrate protein-10 [CFP-10]), and TB7.7 antigen [8,9].…”

Section: Introductionmentioning

confidence: 95%

Use of the QuantiFERON-TB Gold In-Tube Test in the Diagnosis and Monitoring of Treatment Efficacy in Active Pulmonary Tuberculosis

Chang

Wang

Chen

2017

Preprint

View full text Add to dashboard Cite

The value of QuantiFERON in the diagnosis of tuberculosis and in the monitoring of the response to anti-tuberculosis treatment is unclear. The aims of this study were to evaluate the accuracy of the QuantiFERON-TB Gold In-Tube (QFT-GIT) test in the diagnosis of tuberculosis and in the monitoring of the response to anti-tuberculosis treatment in patients with active pulmonary tuberculosis (PTB). Between January 2013 and December 2015, 128 cases with active PTB and 128 controls with no mycobacterial infection, matched by age (within 3 years) and by the week that they visited Tainan Chest Hospital, were enrolled in the study. Serial testing by QFT-GIT at baseline and after 2 and 6 months of treatment was performed. At these time points, a comparison of the performance of QFT-GIT with that of sputum culture status among study subjects was conducted. Compared to baseline, 116 (87.2%) cases showed a decreased response, whereas 17 (12.8%) showed persistent or stronger interferon-gamma (IFN-γ) responses at 2 months. Their IFN-γ responses declined significantly from baseline to 2 months (median, 6.32 vs. 4.12; P < 0.005). The sensitivity values of the QFT-GIT test for the detection of pulmonary tuberculosis at cut-off points of 0.35 IU/ml, 0.20 IU/ml, and 0.10 IU/ml were 74.4%, 78.2%, and 80.5%, respectively. The specificity values at cut-off points of 0.35 IU/ml, 0.20 IU/ml, and 0.10 IU/ml were 66.2%, 63.9%, and 57.1%, respectively. Our results support the QFT-GIT assay as a potential tool for diagnosing tuberculosis and for monitoring the efficacy of anti-tuberculosis treatment.

show abstract